GUTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Fractyl Health Inc (GUTS) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks strong positive catalysts, has bearish technical indicators, and faces significant financial and operational challenges. It is better to wait for clearer signs of improvement in the company's fundamentals or upcoming pivotal data readouts before considering an investment.
The technical indicators show a bearish trend with moving averages in a negative alignment (SMA_200 > SMA_20 > SMA_5). The MACD is positive but contracting, and RSI is neutral at 54.798. The stock is trading near its pivot level of 0.457, with resistance at 0.489 and support at 0.426. Overall, there is no strong technical signal to suggest a buy.
Analysts from H.C. Wainwright maintain a Buy rating with an $8 price target, citing potential positive outcomes from the REMAIN-1 pivotal readout in Q4
The company has approximately $81.5 million in cash, which is expected to fund operations into early
Improved adjusted EBITDA in Q4 2025 reflects some cost control efforts.
Significant financial challenges, including a net loss of $43.7 million in Q4 2025, up from $25 million in Q4
Revenue dropped to zero in Q3 2025, indicating no current income generation.
Analysts from Morgan Stanley downgraded the stock to Equal Weight, citing disappointing weight regain data in the REMAIN-1 midpoint cohort.
Bearish market sentiment with a -5.36% regular market change and -5.96% pre-market change.
Fractyl Health reported a net loss of $43.7 million in Q4 2025, up from $25 million in Q4 2024, highlighting cost pressures. Adjusted EBITDA improved to negative $21.2 million, reflecting cost control efforts. The company had $81.5 million in cash as of December 31, 2025, expected to fund operations into early 2027. However, revenue dropped to zero in Q3 2025, and gross margin fell to 0%, indicating no income generation.
Analyst ratings are mixed. H.C. Wainwright maintains a Buy rating with an $8 price target, citing potential for the REMAIN-1 pivotal readout. However, Morgan Stanley downgraded the stock to Equal Weight with a $2 price target, citing disappointing weight regain data. BofA also lowered its price target to $2, citing imperfect data but remains cautiously optimistic about future pivotal results.
